Publication Name	World Journal of Psychiatry
Manuscript ID	83375
Country	United States

Received	2023-01-19 15:56
Peer-Review Started	2023-01-19 15:58
To Make the First Decision
Return for Revision	2023-02-20 07:28
Revised	2023-02-28 23:49
Second Decision	2023-04-13 03:05
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-04-13 09:14
Articles in Press	2023-04-13 09:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-05-16 06:38
Publish the Manuscript Online	2023-05-19 10:53

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Minireviews
Article Title	Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review
Manuscript Source	Invited Manuscript
All Author List	Lakshan N Fonseka and Benjamin KP Woo
Funding Agency and Grant Number
Corresponding Author	Benjamin KP Woo, MD, Professor, Chinese American Health Promotion Laboratory, University of California, Los Angeles, 3230 Campbell Hall, Los Angeles, CA 90095, United States. bkpwoo@ucla.edu
Key Words	Psychedelics; Trauma; Depression; Methylenedioxymethamphetamine; Ecstasy; Psilocybin
Core Tip	Psychedelic-assisted therapy with psilocybin or 3,4-methylenedioxymethamphetamine (MDMA) is strongly supportive across psychiatric conditions, especially trauma and related comorbidities, as demonstrated through a pattern of rapid and sustained symptom relief. Both treatments seem to have benefits beyond the Food and Drug Administration breakthrough designations of treatment-resistant depression for psilocybin and post-traumatic stress disorder for MDMA.
Publish Date	2023-05-19 10:53
Citation	Fonseka LN, Woo BK. Therapeutic role of psilocybin and 3,4-methylenedioxymethamphetamine in trauma: A literature review. World J Psychiatry 2023; 13(5): 182-190
URL	https://www.wjgnet.com/2220-3206/full/v13/i5/182.htm
DOI	https://dx.doi.org/10.5498/wjp.v13.i5.182

Full Article (PDF)	WJP-13-182.pdf
Full Article (Word)	WJP-13-182.docx
Manuscript File	83375_Auto_Edited-JLW.docx
Answering Reviewers	83375-Answering reviewers.pdf
Audio Core Tip	83375-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	83375-Conflict-of-interest statement.pdf
Copyright License Agreement	83375-Copyright license agreement.pdf
Peer-review Report	83375-Peer-review(s).pdf
Scientific Misconduct Check	83375-Bing-Li L-2.png
Scientific Editor Work List	83375-Scientific editor work list.pdf